secwatch.observer — SEC 8-K summary
======================================

Issuer:     AYTU BIOPHARMA, INC (AYTU)
CIK:        0001385818
Form:       8-K
Filed at:   2023-09-27T23:59:59+00:00
Accession:  0001558370-23-016076
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aytu Q4 record revenue $30.7M, positive Adj. EBITDA $7.7M, prescriptions up 32%
-------------------------------------------------------------------------------

- Q4 net revenue $30.7M (+12% YoY); Rx segment $23.3M (+24%); total prescriptions 155,562 (+32%).
- Net loss improved to $2.5M ($0.59/share) from $16.1M ($8.95/share) a year ago; $0.6M net income excluding impairment.
- Adjusted EBITDA positive $7.7M in Q4 vs negative $3.9M; FY23 Adj. EBITDA positive $3.2M vs negative $21.5M.
- Cash ended at $23.0M, up from $19.2M in March; company plans to monetize or discontinue Consumer Health segment.
- Gross margin improved to 60% (Q4) and 62% (FY) from 54% in both prior-year periods.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1385818/000155837023016076/0001558370-23-016076-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1385818/000155837023016076/aytu-20230927x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-016076

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer